Navigation Links
Galmed Pharmaceuticals Reports First Half 2014 Financial Results
Date:7/25/2014

thereby permitting Galmed to conduct clinical studies for the targeted indication and additional proof of concept studies in the United States in the future.
  • Filed a Fast Track Designation request with the FDA.
  • Published the results of Galmed's Phase IIa trial of aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal.
  • Commenced on schedule, pharmacokinetic and food effect studies in 66 subjects for the higher doses of aramchol that the Company anticipates using in its Phase IIb trial of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH, patients who are also overweight and diabetic.
  • Filed a provisional patent application in the United States for aramchol to treat lipodystrophy, a medical condition characterized by abnormal or degenerative conditions of adipose tissue, or body fat, including the loss of body fat from various regions of the body and its redistribution and accumulation in other areas and for which there is no currently approved medical treatment, based on Galmed's Phase IIa clinical trial of aramchol in 60 non-alcoholic fatty liver disease, or NAFLD, patients, in which a significant reduction in liver fat and improvement of certain metabolic parameters were observed.
  • Independent publication of the importance of the regulation of ABCA1-induced reverse cholesterol transport on the pathogenesis of NASH, which may further support Galmed's belief that aramchol can play a significant role in the pathogenesis of NASH based on Galmed's studies showing the affect of aramchol in increasing ABCA1 activity in in vitro models of human cells by between 300% and 400%.
  • "I am pleased to report that we have completed all short-term milestones that we set for the first half of 2014 at the time of our initial public offering," stated Allen Baharaff, Galmed's Chief Executive Officer. "We are also moving ahead with trial p
    '/>"/>

    SOURCE Galmed Pharmaceuticals Ltd.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
    3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
    4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
    7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
    8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
    9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
    11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... RI (PRWEB) January 22, 2015 Protocol ... , The growing team of brand-neutral, independent consultants, Protocol ... Philip Rogers explained that over the years, his company ... , Moroso, Town of Plainfield, as well as others. ...
    (Date:1/22/2015)... 22, 2015 zFlo Motion , a ... announce an exciting product from a new partner. STT-Systems ... over the past 15 years, with offerings in the optical-motion ... 3D IMU system (inertial measurement unit), iSen, is opening eyes ...
    (Date:1/22/2015)... Selexis SA, a serial innovation company with ... used for drug discovery to commercial manufacturing, announced today ... Next-Generation Sequencing (NGS) data packages. The NGS analysis ... ensuring the integrity of the gene, validation of the ...
    (Date:1/22/2015)...   Cypher Genomics, Inc., the leading genome ... SQNM ), the leading molecular diagnostics company, today ... prenatal tests (NIPT). Through this agreement, Sequenom will ... advance analysis of clinically-relevant fetal sub-chromosomal variants detected ...
    Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 23D Motion Capture Just Got Easy 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4
    ... of the universities in the resund Region University ... together with MC2 at Chalmers University of Technology ... build up a network for co-operation within nanotechnology. , ... , Used efficiently, knowledge on nanotechnology will ...
    ... Required for Integra Merger, IRVINE, California, October 26 ... company, today announced that,it has adjourned its special meeting ... the acquisition of IsoTis by Integra,LifeSciences Holdings Corporation (NASDAQ: ... of merger dated as of August 6, 2007. ...
    ... Services,Inc. (NYSE: AHS ), the nation,s largest ... on Thursday, November 1, 2007 at 3.30 p.m.,Pacific ... place at the San,Diego Marriott Del Mar Hotel ... Susan R. Nowakowski, President and Chief Executive ...
    Cached Biology Technology:IsoTis Adjourns Special Meeting to October 29, 2007 2IsoTis Adjourns Special Meeting to October 29, 2007 3IsoTis Adjourns Special Meeting to October 29, 2007 4AMN Healthcare Services to Present at the BIOCOM Investor Conference 2007 2
    (Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the first ... post-password and Internet of Things era, today announced the ... venture round was led by Metamorphic Ventures with participation ... Partners, VegasTechFund, and others.  LaunchKey has raised $4 million ...
    (Date:12/17/2014)... Dec. 15, 2014 The Defense Logistics Agency is ... and prevent counterfeit microcircuits from entering into its supply ... in-house microcircuit anti-counterfeit initiative dubbed DNA marking. The capability ... their reliability throughout the supply chain. The new quality ...
    (Date:12/17/2014)... 2014 Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ...
    Breaking Biology News(10 mins):LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
    ... and skeletal deformities in people has been shown to ... adult mice, according to a recent study led by ... in early bone development, controls bone mineral density in ... Mutations in matrilin-3 have previously been linked to certain ...
    ... of Minnesota researchers have found a group of cells ... to turn on T-cells, cells that help fight infection. ... 2006 issue of the journal Immunity, released today. , ... response will help in studying and developing treatments for ...
    ... a specific cell protein can trigger the spread of cancer. ... of Edinburgh Cancer Research Centre could pave the way for ... normal cell cancerous. , The protein, MDM2, normally functions ... called p53. In some of the body's cells, the biochemical ...
    Cached Biology News:Matrilin-3 gene discovered to prevent onset of osteoarthritis 2Matrilin-3 gene discovered to prevent onset of osteoarthritis 3
    DITHIOTHREITOL, 150UMOL, 1 EA. Dithiothreitol (DTT), 0.1 M Solution:, *0.1 M solution of DTT in high purity dH2O., *0.2 m filtered., *Storage: -20C. Category: SEQUENASE....
    ... Varian Cary 50 Microplate Reader ... cost per analysis by extending ... the award-winning Cary 50 instruments. ... to 384 samples in microlitre ...
    ... Polynucleotide Kinase for labeling of 5' ... acids. In the exchange reaction T4 ... group from DNA to ADP and ... to the free 5' hydroxyl group ...
    ImageQuant 400, 1 EA. Category: ImageQuant CCD Imagers....
    Biology Products: